Ascendis Financial Statements From 2010 to 2024

ASND Stock  USD 136.38  1.36  0.99%   
Ascendis Pharma financial statements provide useful quarterly and yearly information to potential Ascendis Pharma AS investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Ascendis Pharma financial statements helps investors assess Ascendis Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Ascendis Pharma's valuation are summarized below:
Gross Profit
39 M
Profit Margin
(1.54)
Market Capitalization
8.2 B
Enterprise Value Revenue
24.2076
Revenue
317.6 M
There are over one hundred nineteen available fundamental signals for Ascendis Pharma AS, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Ascendis Pharma's prevailing performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 6.7 B. The current year's Enterprise Value is expected to grow to about 7 B

Ascendis Pharma Total Revenue

280.05 Million

Check Ascendis Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ascendis Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 19.9 M, Interest Expense of 46.3 M or Selling General Administrative of 277.6 M, as well as many indicators such as Price To Sales Ratio of 22.84, Dividend Yield of 0.0 or Days Sales Outstanding of 114. Ascendis financial statements analysis is a perfect complement when working with Ascendis Pharma Valuation or Volatility modules.
  
Check out the analysis of Ascendis Pharma Correlation against competitors.

Ascendis Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets477.4 M825.6 M409.5 M
Slightly volatile
Total Current Liabilities207.2 M197.3 M64.4 M
Slightly volatile
Property Plant And Equipment Net116.2 M110.6 M43.6 M
Slightly volatile
Current Deferred RevenueM1.1 M7.3 M
Slightly volatile
Accounts Payable99.3 M94.6 M32.3 M
Slightly volatile
Cash282.5 M392.2 M242.5 M
Slightly volatile
Non Current Assets Total79.4 M122.9 M68.2 M
Slightly volatile
Non Currrent Assets Other2.2 M2.1 M878.9 K
Slightly volatile
Cash And Short Term Investments339 M399.4 M290.8 M
Slightly volatile
Net Receivables58.6 M55.8 M10.5 M
Slightly volatile
Good Will2.8 M3.1 M3.4 M
Slightly volatile
Common Stock Total Equity4.2 M8.3 M4.5 M
Slightly volatile
Liabilities And Stockholders Equity477.4 M825.6 M409.5 M
Slightly volatile
Non Current Liabilities Total812.6 M773.9 M173 M
Slightly volatile
Other Current Assets40.5 M38.6 M14.6 M
Slightly volatile
Total LiabilitiesB971.3 M228.6 M
Slightly volatile
Property Plant And Equipment Gross191.3 M182.2 M58.8 M
Slightly volatile
Total Current Assets398 M702.7 M341.3 M
Slightly volatile
Common Stock5.2 M7.7 M4.6 M
Slightly volatile
Common Stock Shares Outstanding39.2 M56.3 M32.6 M
Slightly volatile
Net Tangible Assets374.1 M297.3 M272 M
Slightly volatile
Other Assets2.3 M2.2 M894.3 K
Slightly volatile
Other Stockholder Equity2.4 B2.3 B520.2 M
Slightly volatile
Property Plant Equipment155.9 M148.5 M49 M
Slightly volatile
Intangible Assets877.8 K924 K165.4 T
Pretty Stable
Net Invested Capital622 M399.8 M392.7 M
Slightly volatile
Net Working Capital573.3 M505.4 M365.9 M
Slightly volatile
Capital Stock7.8 M7.7 M6.4 M
Slightly volatile

Ascendis Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization19.9 M18.9 M6.4 M
Slightly volatile
Interest Expense46.3 M44.1 M9.9 M
Slightly volatile
Selling General Administrative277.6 M264.4 M75 M
Slightly volatile
Total Revenue280.1 M266.7 M48.8 M
Slightly volatile
Gross Profit233.4 M222.3 M41.7 M
Slightly volatile
Other Operating Expenses758.4 M722.3 M241.3 M
Slightly volatile
Research Development434.1 M413.5 M159.2 M
Slightly volatile
Total Operating Expenses711.8 M677.9 M234.2 M
Slightly volatile
Interest Income17.7 M16.9 M7.3 M
Pretty Stable
Reconciled Depreciation11 M18.9 M5.7 M
Slightly volatile

Ascendis Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation70 M66.7 M26.6 M
Slightly volatile
Begin Period Cash Flow270.1 M444.8 M216.5 M
Slightly volatile
Depreciation19.9 M18.9 M6.2 M
Slightly volatile
Capital Expenditures2.3 M2.4 M5.2 M
Slightly volatile
End Period Cash Flow304.6 M392.2 M243.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio22.8424.0469239
Slightly volatile
Days Sales Outstanding11476.3246109
Very volatile
Stock Based Compensation To Revenue0.240.24992.0625
Slightly volatile
Capex To Depreciation0.120.12911.2425
Pretty Stable
EV To Sales23.7424.9921215
Slightly volatile
Inventory Turnover0.220.21250.0724
Slightly volatile
Days Of Inventory On Hand1.6 K1.7 K6.7 K
Slightly volatile
Payables Turnover0.490.46950.1194
Slightly volatile
Sales General And Administrative To Revenue1.923.262.3733
Slightly volatile
Average Inventory35.6 M33.9 M24.7 M
Slightly volatile
Research And Ddevelopement To Revenue1.471.550213.4817
Pretty Stable
Capex To Revenue0.00870.00920.5457
Slightly volatile
Cash Per Share6.027.09656.5972
Slightly volatile
Days Payables Outstanding7397775.2 K
Slightly volatile
Intangibles To Total Assets0.00510.00540.0492
Slightly volatile
Current Ratio5.623.56096.5191
Slightly volatile
Receivables Turnover9.254.78227.687
Pretty Stable
Graham Number18.8522.319420.1876
Slightly volatile
Capex Per Share0.04120.04340.1133
Slightly volatile
Revenue Per Share4.984.73851.2707
Slightly volatile
Interest Debt Per Share11.010.47381.9847
Slightly volatile
Debt To Assets0.690.66070.1196
Slightly volatile
Operating Cycle1.7 K1.8 K6.8 K
Slightly volatile
Days Of Payables Outstanding7397775.2 K
Slightly volatile
Ebt Per Ebit0.761.04080.9277
Slightly volatile
Long Term Debt To Capitalization0.791.3750.6604
Slightly volatile
Total Debt To Capitalization1.431.36440.2327
Slightly volatile
Quick Ratio2.382.50226.1315
Slightly volatile
Net Income Per E B T0.781.01540.9661
Very volatile
Cash Ratio1.891.98725.3687
Pretty Stable
Cash Conversion Cycle1.4 KK1.6 K
Slightly volatile
Days Of Inventory Outstanding1.6 K1.7 K6.7 K
Slightly volatile
Days Of Sales Outstanding11476.3246109
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.161.00521.1065
Slightly volatile
Fixed Asset Turnover3.912.41084.861
Slightly volatile
Debt Ratio0.690.66070.1196
Slightly volatile
Price Sales Ratio22.8424.0469239
Slightly volatile
Asset Turnover0.20.32310.2382
Slightly volatile
Gross Profit Margin0.570.83360.5821
Slightly volatile

Ascendis Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap6.7 B6.4 B2.9 B
Slightly volatile
Enterprise ValueB6.7 B2.8 B
Slightly volatile

Ascendis Fundamental Market Drivers

Cash And Short Term Investments399.4 M

Ascendis Upcoming Events

15th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ascendis Pharma Financial Statements

Ascendis Pharma stakeholders use historical fundamental indicators, such as Ascendis Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Ascendis Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ascendis Pharma's assets and liabilities are reflected in the revenues and expenses on Ascendis Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ascendis Pharma AS. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.1 MM
Total Revenue266.7 M280.1 M
Cost Of Revenue44.4 M42.2 M
Stock Based Compensation To Revenue 0.25  0.24 
Sales General And Administrative To Revenue 3.26  1.92 
Research And Ddevelopement To Revenue 1.55  1.47 
Capex To Revenue 0.01  0.01 
Revenue Per Share 4.74  4.98 
Ebit Per Revenue(1.71)(1.79)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:
Check out the analysis of Ascendis Pharma Correlation against competitors.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.83)
Revenue Per Share
5.595
Quarterly Revenue Growth
(0.24)
Return On Assets
(0.28)
Return On Equity
(8.18)
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.